Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration

William C Santangelo, Roger H Unger, L. Orci, M. I. Dueno, J. J. Popma, G. J. Krejs

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

A 41-year-old woman with metastatic glucagonoma and the characteristic disabling rash, necrolytic migratory erythema, was treated with a synthetic somatostatin analog while waiting to undergo curative surgical resection. Plasma glucagon concentration (1,500-3,300 pg/ml, normal <200) remained elevated during analog therapy as the rash cleared. Only with surgical resection (partial pancreatectomy and partial hepatectomy) did glucagon levels return to normal. The therapeutic benefit caused by the analog in this syndrome differs from that in other endocrine tumor syndromes such as pancreatic cholera, carcinoid, or gastrinoma where circulating levels of tumor-produced agents are suppressed in conjunction with control of symptoms.

Original languageEnglish (US)
Pages (from-to)464-469
Number of pages6
JournalPancreas
Volume1
Issue number5
DOIs
StatePublished - Sep 1986

Keywords

  • Glucagonoma
  • Necrolytic migratory erythema
  • Somatostatin analog

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Fingerprint Dive into the research topics of 'Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration'. Together they form a unique fingerprint.

  • Cite this